home / stock / cybn / cybn quote
Last: | $0.35 |
---|---|
Change Percent: | -0.74% |
Open: | $0.3526 |
Close: | $0.35 |
High: | $0.3589 |
Low: | $0.3451 |
Volume: | 2,727,669 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.35 | $0.3526 | $0.35 | $0.3589 | $0.3451 | 2,727,669 | 05-03-2024 |
$0.35 | $0.351 | $0.35 | $0.3515 | $0.342 | 1,608,850 | 05-02-2024 |
$0.35 | $0.34 | $0.35 | $0.35 | $0.337 | 2,912,254 | 05-01-2024 |
$0.35 | $0.3468 | $0.35 | $0.3505 | $0.3372 | 3,643,014 | 04-30-2024 |
$0.35 | $0.3507 | $0.35 | $0.3507 | $0.34 | 2,738,229 | 04-29-2024 |
$0.35 | $0.35 | $0.35 | $0.3519 | $0.341 | 2,190,459 | 04-26-2024 |
$0.346 | $0.3501 | $0.346 | $0.3501 | $0.34 | 2,955,743 | 04-25-2024 |
$0.355 | $0.3521 | $0.355 | $0.359 | $0.3372 | 3,514,306 | 04-24-2024 |
$0.355 | $0.3595 | $0.355 | $0.3604 | $0.3513 | 3,048,087 | 04-23-2024 |
$0.3604 | $0.3623 | $0.3604 | $0.38 | $0.355 | 2,295,329 | 04-22-2024 |
$0.3677 | $0.3608 | $0.3677 | $0.373 | $0.36 | 1,779,778 | 04-19-2024 |
$0.3699 | $0.376 | $0.3699 | $0.3799 | $0.3616 | 1,758,327 | 04-18-2024 |
$0.3754 | $0.3795 | $0.3754 | $0.3795 | $0.3662 | 2,083,486 | 04-17-2024 |
$0.3796 | $0.377 | $0.3796 | $0.3797 | $0.3513 | 3,767,037 | 04-16-2024 |
$0.3708 | $0.3741 | $0.3708 | $0.3797 | $0.3608 | 2,834,351 | 04-15-2024 |
$0.366 | $0.3822 | $0.366 | $0.3925 | $0.3557 | 7,443,550 | 04-12-2024 |
$0.38 | $0.4043 | $0.38 | $0.408 | $0.3788 | 4,497,607 | 04-11-2024 |
$0.4 | $0.4195 | $0.4 | $0.42 | $0.383 | 6,721,260 | 04-10-2024 |
$0.4251 | $0.42 | $0.4251 | $0.4298 | $0.4135 | 2,289,133 | 04-09-2024 |
$0.435 | $0.4241 | $0.435 | $0.4355 | $0.4106 | 4,955,641 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cybin Inc. Company Name:
CYBN Stock Symbol:
NYSE Market:
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, is announcing its participation at the 27th Annual Milken Institute Global Conference, set to take place May 5-8, 2024, at th...
- Doug Drysdale, CEO, to appear on panel entitled “Collaborating for Improved Mental Health,” on May 8, 2024 - Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company ...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, is reporting that its research has been published in a prestigious biweekl...